The estimated Net Worth of Theodore Alan Huizenga is at least $4.23 Million dollars as of 3 September 2024. Mr Huizenga owns over 91 units of Ultragenyx Pharmaceutical stock worth over $2,340,568 and over the last 10 years he sold RARE stock worth over $1,893,368.
Mr has made over 33 trades of the Ultragenyx Pharmaceutical stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 91 units of RARE stock worth $5,113 on 3 September 2024.
The largest trade he's ever made was exercising 4,000 units of Ultragenyx Pharmaceutical stock on 7 January 2021 worth over $84,000. On average, Mr trades about 887 units every 62 days since 2015. As of 3 September 2024 he still owns at least 41,551 units of Ultragenyx Pharmaceutical stock.
You can see the complete history of Mr Huizenga stock trades at the bottom of the page.
Theodore A. Huizenga is the VP, Corp. Controller & Principal Accounting Officer at Ultragenyx Pharmaceutical.
Mr Huizenga is 50, he's been the VP and Corp. Controller & Principal Accounting Officer of Ultragenyx Pharmaceutical since . There are 21 older and 3 younger executives at Ultragenyx Pharmaceutical. The oldest executive at Ultragenyx Pharmaceutical Inc. is William Aliski, 73, who is the Independent Director.
Theodore's mailing address filed with the SEC is 60 Leveroni Ct, Novato, CA 94949, USA.
Over the last 11 years, insiders at Ultragenyx Pharmaceutical have traded over $102,813,606 worth of Ultragenyx Pharmaceutical stock and bought 203,500 units worth $4,623,050 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Llc Fmr, and Clay B Siegall. On average, Ultragenyx Pharmaceutical executives and independent directors trade stock every 17 days with the average trade being worth of $573,045. The most recent stock trade was executed by Emil D Kakkis on 3 September 2024, trading 20,000 units of RARE stock currently worth $1,117,000.
ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. our company is led by an experienced management team in rare disease therapeutics. recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. we are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. we are creating an improved model for successful rare disease d
Ultragenyx Pharmaceutical executives and other stock owners filed with the SEC include: